Nidufexor

Nidufexor (LMB-763) is a drug which acts as a partial agonist of the farnesoid X receptor (FXR). It has reached Phase II clinical trials for the treatment of diabetic nephropathy and nonalcoholic steatohepatitis.[1][2]

Nidufexor
Identifiers
IUPAC name
  • 4-{[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl}benzoic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC27H22ClN3O4
Molar mass487.94 g·mol−1
3D model (JSmol)
SMILES
  • CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC=CC=C4)CC5=CC=C(C=C5)C(=O)O
InChI
  • InChI=1S/C27H22ClN3O4/c1-30-25-21-13-20(28)11-12-23(21)35-16-22(25)24(29-30)26(32)31(14-17-5-3-2-4-6-17)15-18-7-9-19(10-8-18)27(33)34/h2-13H,14-16H2,1H3,(H,33,34)
  • Key:JYTIXGYXBIBOMN-UHFFFAOYSA-N

See also

References
  1. Chianelli D, Rucker PV, Roland J, Tully DC, Nelson J, Liu X, et al. (April 2020). "Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis". Journal of Medicinal Chemistry. 63 (8): 3868–3880. doi:10.1021/acs.jmedchem.9b01621. PMID 31940200.
  2. Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E (June 2020). "Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)". Expert Opinion on Investigational Drugs. 29 (6): 623–632. doi:10.1080/13543784.2020.1763302. PMID 32552182. S2CID 219911969.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.